Author

D. Ngabo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:mouse· 2 Organism:non-human primate· 2 Research Focus:cell type annotation· 1 Organism:chicken / avian· 1 Research Focus:differential expression· 1 Organism:rat· 1

Frequent Co-Authors

K. A. Ryan· 5 shared R. J. Watson· 5 shared B. E. Cavell· 4 shared J. Paterson· 4 shared K. E. Gooch· 4 shared K. R. Bewley· 4 shared S. A. Fotheringham· 4 shared Y. Hall· 4 shared

Activity by Year

2020-2021 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

K. A. Ryan

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from disease caused by the Omicron variant

K. A. Ryan, R. J. Watson, K. R. Bewley, C. A. Burton, O. Carnell, B. E. Cavell, A. R. Challis, N. S. Coombes, K. Emery, R. Fell, S. A. Fotheringham, K. E. Gooch, K. Gowan, A. Handley, D. J. Harris, , Y. Hall

This study shows that prior infection with a prototype SARS-CoV-2 strain protects Syrian hamsters from Omicron-induced disease.

bioRxiv · Dec 24, 2021 · PreprintMicrobiology

mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection

S. Rauch, K. E. Gooch, Y. Hall, F. J. Salguero, M. J. Dennis, F. V. Gleeson, D. Harris, C. Ho, H. E. Humphries, S. Longet, D. Ngabo, J. Paterson, E. L. Rayner, K. A. Ryan, S. Sharpe, , M. W. Carroll

This study shows that the mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 infection and reduces disease severity.

bioRxiv · Dec 23, 2020 · PreprintImmunology

Prophylactic intranasal administration of a TLR2 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model

P. C. Proud, D. Tsitoura, R. J. Watson, B. Y. Chua, M. J. Aram, K. R. Bewley, B. E. Cavell, R. Cobb, S. Dowall, S. A. Fotheringham, C. M. Ho, V. Lucas, D. Ngabo, E. Rayner, K. A. Ryan, , M. W. Carroll

bioRxiv · Sep 25, 2020Immunology

Comparison of Rhesus and Cynomolgus macaques as an authentic model for COVID-19.

F. J. Salguero, A. D. White, G. S. Slack, S. A. Fotheringham, K. R. Bewley, K. E. Gooch, S. Longet, H. E. Humphries, R. J. Watson, L. Hunter, K. A. Ryan, Y. Hall, L. Sibley, C. Sarfas, L. Allen, , Tr

This study compares rhesus and cynomolgus macaques as models for mild to moderate COVID-19, showing similar viral replication, immune responses, and histopathology.

bioRxiv · Sep 17, 2020Microbiology

Dose-dependent response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge

K. A. Ryan, K. R. Bewley, S. A. Fotheringham, P. Brown, Y. Hall, A. C. Marriott, J. A. Tree, L. Allen, M. J. Aram, E. Brunt, K. R. Buttigieg, B. E. Cavell, D. P. Carter, R. Cobb, N. S. Coombes, , M Dennis

This study investigates the dose-dependent response of ferrets to SARS-CoV-2 infection, showing protection against re-challenge and mild clinical disease.

bioRxiv · May 29, 2020Microbiology